Beta Drugs Share Price Target 2026 Analyst Forecast Bull and Bear Case
- May 21, 2026
- Posted by: Kashish Aggarwal
- Category: News
The Beta Drugs share price target for 2026 stands at Rs 1,600 as per analyst consensus, implying approximately 20 percent upside from the current market price of Rs 1,320. Investors tracking the Beta Drugs share price target 2026 need to understand the full picture including growth catalysts, FY27 earnings outlook, key risks, and the bull versus bear case scenarios. This article covers every dimension of the Beta Drugs share price target thesis, updated May 2026.
Click Here – Get Free Investment Predictions
Beta Drugs Company Overview
Beta Drugs (NSE: BETA) is a Himachal Pradesh-based Adley Group company specialising in manufacturing and marketing oncology pharmaceutical products including anticancer tablets, capsules, injections, and lyophilized injections, acquiring Nivian Lifesciences in April 2026 to expand its product portfolio. At CMP Rs 1,320 against a 52 week range of Rs 990.1 to Rs 2,000, the stock currently trades at a meaningful discount to its 52 week high, creating a potential re-rating opportunity for investors focused on the Beta Drugs share price target of Rs 1,600. The company’s market capitalisation stands at Rs 1,348 crore.
| Parameter | Value |
|---|---|
| NSE Ticker | BETA |
| Sector | Oncology Pharmaceuticals |
| CMP May 2026 | Rs 1,320 |
| 52 Week High | Rs 2,000 |
| 52 Week Low | Rs 990.1 |
| Market Cap | Rs 1,348 crore |
| Trailing P/E | 130x |
| 12M Analyst Target | Rs 1,600 |
| Bull Case Target | Rs 1,900 |
| Bear Case Target | Rs 1,050 |
Why Is Beta Drugs Share Price Target Set at Rs 1,600 for 2026
FY27 Earnings Delivery and Revenue Acceleration
FY27 is the pivotal year for the earnings recovery thesis underpinning the Beta Drugs share price target 2026 of Rs 1,600. Analysts project 15 to 20 percent PAT growth in FY27 as operational leverage and strategic investments begin contributing meaningfully to the top line. Q4 FY26 results with positive FY27 guidance are the immediate trigger for re-rating toward the Beta Drugs share price target forecast. This FY27 earnings delivery is the primary variable that bridges the current CMP of Rs 1,320 with the Beta Drugs share price target of Rs 1,600.
Structural Sector Tailwinds in Oncology Pharmaceuticals
India’s pharmaceutical sector is growing on the back of rising healthcare expenditure, USFDA approvals, and expanding generic drug export markets globally. Beta Drugs’s market position and operational expertise create a compounding growth runway that directly supports the Beta Drugs share price target consensus of Rs 1,600. Improving sectoral fundamentals are expected to accelerate earnings momentum through FY27, reinforcing the Beta Drugs share price target 2026 bull case of Rs 1,900.
RBI Rate Cut Cycle and Lower Cost of Capital
India’s RBI rate cut cycle, which commenced in early 2026, reduces Beta Drugs’s borrowing costs and stimulates demand across its end markets. Lower interest costs improve EBITDA to PAT conversion, directly expanding EPS and supporting the Beta Drugs share price target 2026 of Rs 1,600. Any further rate cuts through FY27 compound this benefit and add upside optionality toward the bull case Beta Drugs share price target of Rs 1,900.
Union Budget 2026 Policy Support
Union Budget 2026-27’s Rs 11.21 lakh crore infrastructure capex, PLI scheme continuity, and consumption demand incentives create a positive policy backdrop for Beta Drugs’s Oncology Pharmaceuticals business. These policy tailwinds directly support the Beta Drugs share price target 2026 bull case and improve the probability of achieving the Rs 1,600 analyst estimate over the next 12 months.
Improving FII Flows Post US Tariff Shock
As macro conditions normalise post the April 2026 US tariff shock, FII flows into quality Indian companies are expected to recover through FY27, directly supporting the Beta Drugs share price target of Rs 1,600. Beta Drugs’s valuation at 130x P/E relative to sector peers positions it as a potential beneficiary of institutional reallocation as sentiment normalises across Indian equities.
Screen the best stocks on the Univest Screener.
Beta Drugs Share Price Targets: Short Term, 12 Month, and Long Term
Short Term Target: 3 to 6 Months
The short term Beta Drugs share price target is anchored to the 52 week low support zone near Rs 990.1. In the 3 to 6 month timeframe, a recovery toward 10 to 15 percent above current levels is the base case if Q4 FY26 results confirm the earnings recovery trajectory. Any positive operational update could serve as a near-term re-rating trigger toward the full Beta Drugs share price target 2026 of Rs 1,600.
12 Month Beta Drugs Share Price Target 2026
The 12 month Beta Drugs share price target 2026 is Rs 1,600, implying approximately 20 percent upside from CMP Rs 1,320. This base case assumes in-line FY27 earnings delivery, partial normalisation of FII flows, and continued execution on strategic priorities. Track the live Beta Drugs share price target data on NSE ticker BETA.
Long Term Target: FY27 to FY28
For investors with a 2 to 3 year horizon, the long term Beta Drugs share price target is Rs 1,900 in the bull case. Full FY27 to FY28 earnings delivery, strategic expansion, and sector re-rating toward higher peer multiples are the conditions required. The long-term Beta Drugs share price target thesis rests on Beta Drugs’s market leadership and expanding addressable opportunity in the Oncology Pharmaceuticals space.
Bull Case and Bear Case for Beta Drugs Share Price Target
Bull Case Beta Drugs Share Price Target Rs 1,900
The bull case for the Beta Drugs share price target of Rs 1,900 materialises if FY27 earnings exceed analyst estimates, sector tailwinds accelerate beyond consensus, and FII flows return to quality Indian names. Under this scenario, the stock re-rates toward higher earnings multiples, making the Beta Drugs share price target of Rs 1,900 achievable within FY27 to FY28.
Bear Case Beta Drugs Share Price Target Rs 1,050
The bear case sees the Beta Drugs share price target testing Rs 1,050 if FY27 earnings guidance disappoints and FII outflows from Indian equities persist. At Rs 1,050, the stock would revisit near the 52 week low support zone of Rs 990.1, requiring a full reassessment of the Beta Drugs share price target thesis before fresh targets can be assigned.
| Scenario | Price Target | Conditions |
|---|---|---|
| Bull Case | Rs 1,900 | FY27 earnings beat, sector re-rating, FII inflows, macro normalisation |
| Base Case Analyst Forecast | Rs 1,600 | In-line FY27 delivery, partial FII recovery, steady execution |
| Bear Case | Rs 1,050 | FY27 guidance cut, earnings miss, persistent FII outflows |
Key Risks to the Beta Drugs Share Price Target 2026
US Tariff Macro Headwind
The 26 percent US reciprocal tariff announced April 2, 2026 created FII outflow pressure across Indian equities including Beta Drugs. Prolonged trade tension or global demand slowdown remains a key downside risk to the Beta Drugs share price target 2026 of Rs 1,600.
Valuation and Earnings Miss Risk
At 130x P/E, any FY27 earnings miss or guidance cut could trigger multiple compression, posing the most immediate risk to the Beta Drugs share price target 2026 of Rs 1,600. Investors should monitor quarterly results closely for confirmation of the earnings recovery trajectory.
Competitive Pressure in Oncology Pharmaceuticals
Intensifying competition in the Oncology Pharmaceuticals space could compress Beta Drugs’s pricing power and market share over the medium term. This is a structural risk that investors should weigh when evaluating the Beta Drugs share price target of Rs 1,600 at current levels.
FII Selling Pressure and Liquidity Risk
Global risk-off events can trigger institutional selling, disconnecting price from fundamental value. Sustained FII outflows could delay re-rating toward the Beta Drugs share price target regardless of company-level improvement through FY27.
How to Invest in Beta Drugs
- Research the Fundamentals: Analyse Beta Drugs’s quarterly results, balance sheet, and strategic developments before making any investment decision based on the Beta Drugs share price target 2026 of Rs 1,600.
- Open a Demat Account: Buy Beta Drugs (NSE: BETA) through any SEBI registered broker to invest with full regulatory protection.
- Plan Your Entry: Key support is near Rs 990.1 at the 52 week low. A confirmed FY27 earnings uptick would strengthen the entry case toward the Beta Drugs share price target of Rs 1,600.
- Position Sizing: Allocate a maximum of 3 to 5 percent of your portfolio to any single stock to manage concentration and liquidity risk effectively.
- Consult a SEBI Registered Advisor: Always seek guidance from a SEBI registered financial advisor before investing based on any Beta Drugs share price target estimate. SEBI Registration No. INH000013776.
Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.
FAQs on Beta Drugs Share Price Target 2026
What is the Beta Drugs share price target for 2026?
The Beta Drugs share price target 2026 is Rs 1,600 based on analyst estimates, implying approximately 20 percent upside from the current CMP of Rs 1,320. The bull case is Rs 1,900 and the bear case is Rs 1,050.
Is Beta Drugs a good buy at CMP Rs 1,320?
At Rs 1,320, the stock offers potential upside to the Beta Drugs share price target 2026 of Rs 1,600 if FY27 earnings recover as projected. Investment suitability depends on individual risk tolerance and time horizon. Consult a SEBI registered financial advisor before investing.
What is the 52 week high and low of Beta Drugs?
The 52 week high of Beta Drugs is Rs 2,000 and the 52 week low is Rs 990.1. At CMP Rs 1,320, the stock is below its 52 week peak, creating upside potential to the Beta Drugs share price target 2026 of Rs 1,600.
What are the main risks to the Beta Drugs share price target?
Key risks to the Beta Drugs share price target of Rs 1,600 include US tariff-driven FII selling, earnings miss risk, competitive pressure in Oncology Pharmaceuticals, and broader market volatility. Monitor quarterly results for confirmation of the recovery trajectory.
What are the key catalysts for the Beta Drugs share price target?
Primary catalysts for the Beta Drugs share price target 2026 include FY27 PAT recovery, sector tailwinds in Oncology Pharmaceuticals, RBI rate cut support, Budget policy uplift, and FII flow normalisation into quality Indian equities through FY27.
Where can I track Beta Drugs live price and analyst data?
Track the Beta Drugs share price target and live price on NSE (ticker: BETA). Financial data platforms provide quarterly results, margins, and peer comparisons to assess the Rs 1,600 analyst estimate thesis in real time.
What is the Beta Drugs share price target for 2027?
For FY27 to FY28, the long term Beta Drugs share price target is Rs 1,900 in the bull case, assuming earnings acceleration, sector re-rating, and FII flow recovery. Consult a SEBI registered financial advisor for personalised investment guidance.
How can I buy Beta Drugs shares?
You can buy Beta Drugs (NSE: BETA) through any SEBI registered stockbroker by opening a Demat and trading account online. Research the Beta Drugs share price target on verified financial platforms and always set a disciplined entry, target, and stop loss before investing.
Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. All analyst targets are estimates based on publicly available data as of May 2026. Consult a SEBI registered financial advisor before investing. SEBI Registration No. INH000013776.
